Dr. Reddy's Q1 FY26 Financial Results

This collection of documents details the unaudited financial results for Dr. Reddy's Laboratories Limited for the quarter ending June 30, 2025. The primary source is a press release from Dr. Reddy's, accompanied by a letter to various stock exchanges (National Stock Exchange of India, BSE Limited, New York Stock Exchange, NSE IFSC Ltd.) announcing the board's approval of these results. The documents include consolidated and standalone financial statements prepared under both International Financial Reporting Standards (IFRS) and Indian Accounting Standards, along with limited review reports from their statutory auditors. Key financial highlights such as revenues, gross profit, R&D expenses, profit before and after tax, and earnings per share are presented, alongside segment-wise revenue breakdowns and business updates like new partnerships, product launches, and regulatory observations. The materials also touch upon significant events, including the acquisition of Haleon's Nicotine Replacement Therapy business, a stock split, and an ongoing investigation related to alleged improper payments in Ukraine.

There are no comments yet.

Please log in to write the first comment.